In addition to Dr Ward, London Genetics has appointed
Pharmacogenetics is the study of how our genetic make-up affects the way
in which we metabolise and respond to drugs. As a result, it is expected to
play a key role in the future of drug development and healthcare delivery as
the industry faces increasing pressure to replenish its pipeline and improve
drug safety. By combining its access to genetic expertise with strategic
advice on the application of pharmacogenetics in drug development, London
Genetics can help companies meet this need for smarter, faster and safer drug
development. Chief Scientific Officer Dr
Given its access to the resources of its founding partners, London Genetics has broad therapeutic experience with a particular focus on cardiovascular drugs and cardiovascular safety. The company will be holding its inaugural state-of-the-art conference in September (1), which will focus on how pharmacogenetics adds value to drug development and patient care, in particular in the cardiovascular area.
Commenting on his appointment, Dr Ward said 'I am delighted to have joined the strong team at London Genetics at a time when the importance of pharmacogenetics in drug development is becoming increasingly clear. This is a pivotal phase of the company's development as it works in partnership with biopharmaceutical companies to add value to drug development programmes'. Ms Kleyn added 'We have an exciting partnering programme lined up for the coming months and I look forward to working together with our founding institutions and the biopharmaceutical industry to build interactions that will help to make a difference to drug development.'
(1) London Genetics Limited Pharmacogenetics Conference - Harnessing Genetic Knowledge To Improve Clinical Development and Patient Care.
Pictures of Dr Ward, Ms Kleyn, Dr Caulfield and Dr Foot available on request
Notes to Editors:
About London Genetics
London Genetics Limited is a not-for-profit company which expedites
pharmacogenetic and biomarker partnerships between industry and academia for
more effective targeted drug development, and addition of value to marketed
medicines. Established in 2007 with funding from the London Development
Agency, its seven founding partners are leading
Genetic differences between individuals means that drug response rates are often variable across a population, and this has significant healthcare cost effectiveness implications. Pharmocogenetics, the study of the clinical consequences of genetic differences in the way people metabolise and respond to drugs, is expected to generate better understanding of how drugs work in the body, and therefore give insight into how to develop more efficacious and safer drugs. It also has implications for product life cycle management and the revitalisation of drugs which previously failed in clinical trials. With drug development costs rising and R&D productivity falling, plus increased regulator focus on safety and cost-effectiveness, pharmacogenetics is expected to become increasingly important in drug development. The FDA and the EMEA have recognised this in their Critical Path Initiative and Road Map respectively.